Conversely, decreased levels of cMGP as found in PXE may result in increased expression of VEGF, which is suggested to play a major role in the pathogenesis of CNV and subsequent vision loss in PXE patients as repeated intravitreal injections of anti-VEGF antibodies, like bevacizumab, were found to be very effective in treating this specific ocular complication [45,46,47]. The gene discussed is VEGFA; the disease is autosomal recessive inherited pseudoxanthoma elasticum.